By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed rights from Health Discovery Corp. and privately held firm Smart Personalized Medicine to develop laboratory tests that help determine appropriate breast cancer therapies.

The firms did not provide details on the licensed technologies. Under the terms of the agreements, Quest will pay health Discovery and SPM upfront licensing payments, development fees, and royalties on a per test basis.

Further terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.